Invest in Sensore
Invest in Sensore
Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.
A patented medical device platform designed to reduce one of healthcare's most costly and preventable conditions, now in paid pilots with UK care providers.
Raising £950k (EIS Approved) to complete regulatory and commercial inflection milestones in 2026, with planned launch in early 2027.
Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.
A patented medical device platform designed to reduce one of healthcare's most costly and preventable conditions, now in paid pilots with UK care providers.
Raising £950k (EIS Approved) to complete regulatory and commercial inflection milestones in 2026, with planned launch in early 2027.
60+
Device Pilots
400+
on Waitlist
£950k
Seed Raise
class i
Medical Device
2025 was a year of material progress for Sensore, marking a transition from
validation to execution and building the foundations for clinical and commercial scale.
2025 was a year of material progress for Sensore,
marking a transition from validation to execution
and building the foundations for clinical and commercial scale.
2025 was a year of material progress for Sensore, marking a transition from validation to execution and building the foundations for clinical and commercial scale.
Patent Granted
Core sensor technology protected by granted patent GB2602155.
Paid Pilots
Paid pilots with UK national care home & domiciliary care groups validates clinical need, willingness to pay, and real-world integration.
Regulatory Pathway
A clear UK, EU & FDA regulatory pathway established, with expert support from London Institute for Healthcare Engineering.
Key New Hires
Strategic hires across clinical, regulatory, and commercial leadership strengthen execution capability.
2026: Certification & Scale
These milestones put Sensore in a strong position to scale in 2026, focused on delivering our funded clinical usability study, preparing UKCA submission and converting early pilots - towards a planned launch in 2027.
These milestones put Sensore in a strong position to scale in 2026, focused on delivering our funded clinical usability study, preparing UKCA submission & converting early pilots - towards a planned launch in 2027.
Why Invest Now?
Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.
Execution Phase
Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.
This raise funds execution and scale, not product proof.
Persistent, High-Cost Problem
Commercial Validation
Defined Regulatory Pathway
Near-Term Value Inflection
Timing Is Right
Why Invest Now?
Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.
Execution Phase
Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.
This raise funds execution and scale, not product proof.
Persistent, High-Cost Problem
Commercial Validation
Defined Regulatory Pathway
Near-Term Value Inflection
Timing Is Right
Why Invest Now?
Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.
Execution Phase
Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.
This raise funds execution and scale, not product proof.
Persistent, High-Cost Problem
Commercial Validation
Defined Regulatory Pathway
Near-Term Value Inflection
Timing Is Right
supported by
Request a Conversation
Request a Conversation
We are engaging with aligned EIS investors to anchor our seed round and welcome direct conversations and warm introductions.
We are engaging with aligned EIS investors to anchor our seed round and welcome direct conversations and warm introductions.